SGLT2 inhibitors with metformin do not increase fracture risk in diabetics: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-08-21 05:45 GMT | Update On 2020-08-21 12:26 GMT

China: Combination therapy with SGLT2 inhibitors and metformin in patients with type 2 diabetes (T2D) does not increase fracture risk versus metformin monotherapy, according to a recent study in the journal Osteoporosis International.

According to the authors, no study has evaluated the association between sodium-glucose transporter-2 inhibitors (SGLT2is) and metformin use and fracture risk. Therefore the aim of this study by

B-B. Qian, The Second Clinical College of Dalian Medical University, Yangzhou, Jiangsu, China, and colleagues was to investigate the fracture risk of SGLT2is and metformin combination therapy in T2D patients.

The researchers scrutinized online databases for all eligible randomized controlled trials (RCTs). The summarized odds ratios (ORs) and their 95% confidence intervals (CI) were calculated using Review Manager 5.3 software.

A total of 25 RCTs involving 19,500 participants with T2D were included in this study.

Also Read: Metformin use may increase hospitalisation in COPD with diabetes, says study

Key findings of the study include:

There were 88 fracture cases in the SGLT2is in combination with metformin therapy group and 79 in the control group.
SGLT2is combined with metformin use did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM.
After stratification by drug type, follow-up time, control regimen, and type of fracture, the upshots were still stable.

"The results of our meta-analysis manifested no detrimental effect of SGLT2is combined with metformin therapy on fracture risk in T2DM patients. When stratified by control regimen, drug type, follow-up duration, and type of fracture, we still did not see a significant difference in the two sets of results," wrote the authors.

"SGLT2is and metformin combination therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM," they concluded.

Also Read: Prescribe SGLT2 inhibitors or GLP1 receptor agonists to reduce CV risk in diabetes: Expert Consensus

The study, "Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials," is published in the journal Osteoporosis International.

DOI: https://doi.org/10.1007/s00198-020-05590-y

Article Source : journal Osteoporosis International

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SGLT2 inhibitors with metformin do not increase fracture risk in diabetics: Study

Similar News

Machine Learning Flags Key Risks for Early Macular Degeneration: Hypertension, Joint Disorders, and Dyslipidemia: Study

Once-Weekly Semaglutide-Insulin Combo Matches Daily Basal-Bolus in Type 2 Diabetes Control: Study

Vitamin D Supplementation Shows Potential Benefit in MAFLD Management: Study

Diabetes May Increase Risk of Complications After Knee Replacement, Finds An Indian Meta-Analysis

Consuming more protein may protect patients taking anti-obesity drug from muscle loss: Study

Lupin wins USFDA nods for Liraglutide, Glucagon Injectable Products

GLP-1 Receptor Agonists Use Linked to Lower Cardiovascular Risk in Diabetic Patients with MGUS: Study

Nighttime pistachio snacking may reshape gut microbiome in prediabetic adults: Study